Compare · MASS vs TMO
MASS vs TMO
Side-by-side comparison of 908 Devices Inc. (MASS) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MASS and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $232.47B, about 515.0x MASS ($451.4M).
- Over the past year, MASS is up 73.8% and TMO is up 28.1% - MASS leads by 45.7 points.
- MASS has been more active in the news (12 items in the past 4 weeks vs 10 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 6 for MASS).
- Company
- 908 Devices Inc.
- Thermo Fisher Scientific Inc
- Price
- $10.91+2.63%
- $628.86-0.07%
- Market cap
- $451.4M
- $232.47B
- 1M return
- +53.09%
- +10.69%
- 1Y return
- +73.81%
- +28.13%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 12
- 10
- Recent ratings
- 6
- 25
908 Devices Inc.
908 Devices Inc. develops and sells measurement devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and the Asia Pacific. It offers handheld and desktop mass spectrometry (Mass Spec) devices for the point-of-need applications in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest MASS
- Large owner Awm Investment Company, Inc. sold $529,797 worth of shares (50,000 units at $10.60) (SEC Form 4)
- President and CEO Knopp Kevin J. sold $283,677 worth of shares (27,622 units at $10.27) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 555,968 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by 908 Devices Inc.
- Director Brown Christopher D. sold $162,406 worth of shares (17,800 units at $9.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 805,559 units (SEC Form 4)
- President and CEO Knopp Kevin J. sold $1,475,145 worth of shares (149,013 units at $9.90) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 583,590 units (SEC Form 4)
- 908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference
- SEC Form 10-Q filed by 908 Devices Inc.
- 908 Devices Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- 908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
- Director Brown Christopher D. sold $169,800 worth of shares (20,000 units at $8.49) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 823,359 units (SEC Form 4)
Latest TMO
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 31 shares, decreasing direct ownership by 0.53% to 5,830 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 20,000 shares at a strike of $309.63 and sold $12,561,823 worth of shares (20,000 units at $628.09) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. sold $7,014,093 worth of shares (11,440 units at $613.12) and exercised 11,440 shares at a strike of $418.32, decreasing direct ownership by 0.00% to 14,784 units (SEC Form 4)
- Executive Vice President Shafer Michael D exercised 25,500 shares at a strike of $370.58 and sold $15,300,000 worth of shares (25,500 units at $600.00) as part of a pre-agreed trading plan (SEC Form 4)
- Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg
- VP & Chief Accounting Officer Holmes Joseph R. exercised 420 shares at a strike of $309.63 and sold $245,620 worth of shares (420 units at $584.81) (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 275 shares at a strike of $309.63 and sold $2,862,002 worth of shares (4,883 units at $586.12) as part of a pre-agreed trading plan (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. exercised 5,850 shares at a strike of $309.63 and sold $3,393,000 worth of shares (5,850 units at $580.00), decreasing direct ownership by 0.00% to 14,784 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 10,000 shares at a strike of $309.63 and sold $8,616,967 worth of shares (15,000 units at $574.46) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 10,000 shares at a strike of $309.63 and sold $8,628,434 worth of shares (15,000 units at $575.23) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)